Retrophin Inc (RTRX) : Lombard Odier Asset Management (usa) Corp scooped up 135,003 additional shares in Retrophin Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,279,723 shares of Retrophin Inc which is valued at $22,177,600.Retrophin Inc makes up approximately 2.95% of Lombard Odier Asset Management (usa) Corp’s portfolio.
Other Hedge Funds, Including , Analytic Investors sold out all of its stake in RTRX during the most recent quarter. The investment firm sold 93,756 shares of RTRX which is valued $1,624,791.Blackrock Investment Management boosted its stake in RTRX in the latest quarter, The investment management firm added 28,119 additional shares and now holds a total of 147,822 shares of Retrophin Inc which is valued at $2,561,755.First Mercantile Trust Co boosted its stake in RTRX in the latest quarter, The investment management firm added 1,550 additional shares and now holds a total of 5,930 shares of Retrophin Inc which is valued at $102,767. Retrophin Inc makes up approx 0.01% of First Mercantile Trust Co’s portfolio.Alambic Investment Management boosted its stake in RTRX in the latest quarter, The investment management firm added 1,550 additional shares and now holds a total of 18,800 shares of Retrophin Inc which is valued at $328,060. Retrophin Inc makes up approx 0.07% of Alambic Investment Management’s portfolio.
Retrophin Inc opened for trading at $16.09 and hit $16.75 on the upside on Thursday, eventually ending the session at $16.35, with a gain of 2.06% or 0.33 points. The heightened volatility saw the trading volume jump to 4,10,672 shares. Company has a market cap of $601 M.
On the company’s financial health, Retrophin Inc reported $0.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.18 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.11. The company had revenue of $33.30 million for the quarter, compared to analysts expectations of $32.69 million. The company’s revenue was up 38.2% compared to the same quarter last year.
Retrophin Inc. (Retrophin) is a biopharmaceutical company. The Company is focused on the discovery acquisition development and commercialization of drugs for the treatment of debilitating and life-threatening diseases. The Company is focused on various catastrophic diseases affecting children including focal segmental glomerulosclerosis (FSGS) and pantothenate kinase-associated neurodegeneration (PKAN). The Company is engaged in enrolling patients in a Phase II clinical trial for its lead compound Sparsentan for FSGS. The Company’s products include Thiola (Tiopronin) and Chenodal. Its Thiola is used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Chenodal is a tablet of chenodiol (chenodeoxycholic acid). Its other products include RE-024 and RE-034 which are in pre-clinical stage.